GlassScriptPhysician profile
Mark L Decco
NPI 1912083106
$4,878.30
in general payments reported to CMS, 2019-2025
20 companies · $1,109 in 2025
The $1,109 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $123 · 2021: $334 · 2022: $615 · 2023: $1,195 · 2024: $1,033 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,038 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,038.05 |
| Education | $298.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,075.40 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,039.36 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $998.88 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $400.98 | 2019-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $298.84 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $198.94 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $177.87 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $124.28 | 2023-2025 | |
| Genentech USA, INC. | $113.97 | 2019-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $62.10 | 2023 | Hyqvia, Cuvitru |
| Hikma Pharmaceuticals USA | $58.32 | 2023-2024 | Ryaltris |
| Alk-Abello, INC | $56.74 | 2019-2021 | |
| Csl Behring | $55.01 | 2022-2025 | Andembry |
| Kaleo, INC. | $53.19 | 2023 | Auvi-Q |
| Octapharma USA, INC. | $46.56 | 2023-2024 | Panzyga |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.17 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $23.02 | 2023 | |
| Biocryst US Sales Co., LLC | $22.19 | 2023 | Orladeyo |
| Covis Pharma Gmbh | $19.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.83 | 2023 | Airduo Digihaler |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Decco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.